Healthcare / BiotechnologyTel Aviv
$678.90
+5.10 (+0.76%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-19.8M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$73M
P/E
N/A
•EV/EBITDA
N/A
•ROE
330.1%
↑Gross Margin
49.0%
↑Debt/Equity
-4.98
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+78.7%
FCF CAGR
—
FCF margin
-1484.2%
FCF / Net income
0.88x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.3M · net income $-22.6M · FCF $-19.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3M | $1.3M | $326000.00 | $287000.00 | $234000.00 |
| Net Income | $-22.6M | $-22.6M | $-20.9M | $-28.3M | $-41.2M |
| EBITDA | $-22.1M | $-22.1M | $-20.2M | $-27.7M | $-39.4M |
| EPS | -3.56 | -3.56 | -3.99 | -6.24 | -10.24 |
| Gross Margin | 49.0% | 49.0% | 98.8% | 96.9% | 100.0% |
| Operating Margin | -1659.9% | -1659.9% | -6796.9% | -9493.4% | -17774.8% |
| Net Margin | -1690.3% | -1690.3% | -6407.4% | -9867.9% | -17624.8% |
| Balance Sheet | |||||
| Debt/Equity | -4.98 | -4.98 | 308.46 | 2.24 | 0.96 |
| Current Ratio | 0.33 | 0.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-19.8M | $-19.8M | $-18.3M | $-23.1M | $-36.8M |
| Returns | |||||
| ROE | 330.1% | 330.1% | -21758.3% | -212.1% | -137.3% |
| Valuation | |||||
| P/B | — | — | 118997.32 | 972.08 | 480.11 |
| Growth & Yield | |||||
| Revenue Growth | 309.8% | 309.8% | 13.6% | 22.6% | — |
| EPS Growth | 10.8% | 10.8% | 36.1% | 39.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-57.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.99 → -3.56
Residual
-57.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.